|
| Press Releases |
|
 |
|
| Wednesday, March 6, 2024 |
|
|
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S. more info >> |
|
|
エーザイ、早期アルツハイマー病の診断の簡便化を支援するためC2N Diagnostics LLCに出資 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社米国子会社エーザイ・インクが、C2N Diagnostics LLC（本社：米国ミズーリ州セントルイス 以下 C2N）による米国におけるアルツハイマー病（AD）の血液診断の実用化ならびに、アクセス、アフォーダビリティ、および利用の拡大に向けた取り組みを支援するため、同社に最大15百万米ドルの出資を決定したことをお知らせします。 more info >> |
|
| Thursday, February 29, 2024 |
|
|
エーザイ、第18回アルツハイマー・パーキンソン病学会（AD/PDTM2024）において、レカネマブをはじめとするアルツハイマー病に関する最新研究成果を発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、抗Aβプロトフィブリル＊抗体レカネマブ（一般名、製品名「レケンビ」、米国ブランド名「LEQEMBI」）をはじめとする当社のアルツハイマー病（AD）ポートフォリオに関する最新研究成果について、口頭発表10演題を含む合計18演題を、3月5日から９日までポルトガル・リスボンおよびバーチャルで開催される「第18回アルツハイマー・パーキンソン病学会（International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders：AD/PD™ 2024）において発表することをお知らせします。 more info >> |
|
| Wednesday, February 21, 2024 |
|
|
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 |
| Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions. more info >> |
|
| Monday, November 20, 2017 |
|
|
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December |
| Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Friday, November 17, 2017 |
|
|
エーザイ、ドイツにおいて公的医療保険中央連合会との合意に基づき、抗てんかん剤「Fycompa(R)」の販売を12月に再開 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、ドイツ医薬品販売会社である Eisai GmbH（所在地：フランクフルト）が、抗てんかん剤「Fycompa(R)」（一般名：ペランパネル、日本製品名「フィコンパ(R)」)について、公的医療保険中央連合会（GKV-Spitzenverband）と償還価格に関して合意し、2017年12月1日よりドイツでの「Fycompa」の販売を再開することをお知らせします。 more info >> |
|
| Monday, November 6, 2017 |
|
|
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen Inc. (Nasdaq: BIIB) presented new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, an investigational treatment for Alzheimer's disease at the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting, Boston, Massachusetts, United States, from November 1 to 4. more info >> |
|
| Tuesday, July 14, 2020 |
|
|
エーザイとバイオジェン、BAN2401についてプレクリニカル（無症状期）アルツハイマー病を対象とした新たな臨床第III相試験（AHEAD 3-45）を開始 |
| Alzheimer's Clinical Trials Consortium、エーザイ株式会社とバイオジェン・インクは、このたび、抗アミロイドB（AB）プロトフィブリル抗体BAN2401 について、臨床症状は正常で、AD のより早期ステージにあたる脳内 AB蓄積が陽性*のプレクリニカル AD および脳内 AB蓄積が境界域レベルの早期プレクリニカル AD を対象とした臨床第III相試験（AHEAD 3-45）を米国において開始したことをお知らせします。 more info >> |
|
|
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease |
| The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe. more info >> |
|
| Monday, July 13, 2020 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded |
| Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 2, 2026 22:00 HKT/SGT
|
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb 2, 2026 21:00: JST
|
|
|
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor
Feb 2, 2026 20:30 HKT/SGT
|
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb 2, 2026 20:00 HKT/SGT
|
|
|
君圣泰医药任命Filip Surmont博士为首席医学官 强化心肾代谢系统疾病（CKM）布局
Feb 2, 2026 18:39 HKT/SGT
|
|
|
卡奧斯遞交招股書：技術築牢根基 盈利穩步增長
Feb 2, 2026 15:46 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 2, 2026 16:29 JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 14:29: JST
|
|
|
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 2, 2026 14:30 JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 13:29 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 13:17 HKT/SGT
|
|
|
富士通、ＳＭＢＣ日興証券様のオンライン取引の不正アクセス対策として、生体認証サービスを導入
Feb 2, 2026 12:30: JST
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 08:00 HKT/SGT
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 18:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
